Osteosarcoma Market Size was valued at USD 0.64 Billion in 2023. The Global Osteosarcoma industry is projected to grow from USD 0.69 Billion in 2024 to USD 1.21 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.39% during the forecast period (2024 - 2032).
Osteosarcoma is a common type of bone cancer that is developed in cells that are responsible for the formation of bones. In very rare conditions osteosarcoma occurs in the soft tissue outside the bones. Generally, it mostly occurs in teenagers, young adults, and older adult population.
The osteosarcoma market is primarily driven by the high incidence of osteosarcoma, rising expenditure on oncology medicine and research, and the rising demand for new treatments. However, the high cost of treatment and side-effects of chemotherapy are hampering the growth of the market.
Market Dynamics
The Osteosarcoma Market is emerging due to the high incidence of osteosarcoma. For instance, the prevalence of primary bone cancer is increasing across the world. According to the National Institutes of Health (NIH), an estimate of around 3,450 new cases of primary bone cancer was registered in 2018 in the US. A high number of incidences of osteosarcoma would support the growth of the market. According to the American Cancer Society, around 800 to 900 new cases of osteosarcoma are diagnosed in the US each year. The incidence of osteosarcoma is found to be high in adolescents and the geriatric population. Similarly, according to an article published in the North American Association of Central Cancer Registries, about 3,809 incident cases of osteosarcoma were identified in patients aged 40 years or older in 2018.
Moreover, the National Cancer Institute's Surveillance, Epidemiology, and End Results Program estimated the incident rate of 4.4 cases per 1 million people below the age of 24 years in the US each year. This cumulative prevalence of osteosarcoma along with the rising geriatric population are driving the osteosarcoma market.
The Osteosarcoma Market has been segmented into type, diagnosis & treatment, end-user, and region.
On the basis of type, the Osteosarcoma Market has been segmented into intramedullary osteosarcoma, juxtacortical osteosarcoma, and extraskeletal osteosarcoma. Intramedullary osteosarcoma is estimated to account for the largest market share of 80.3% during the forecast period. Intramedullary osteosarcoma is the most common type of osteosarcoma, which represents approximately 75% of all reported osteosarcoma cases recorded globally. Usually, intramedullary osteosarcoma occurs in children and adults. This type of osteosarcoma is bimodal and primarily peaks during adolescence, and the second peak occurs in adulthood. The distal femur and proximal tibia are two primary sites affected by intramedullary osteosarcoma.
On the basis of diagnosis & treatment, the osteosarcoma market has been segregated into treatment and diagnosis. The treatment segment is further segmented into chemotherapy, surgery, radiation therapy, and others. The chemotherapy segment includes cisplatin, doxorubicin, epirubicin, and others. The surgery segment includes limb-sparing surgery and amputation.
The diagnosis segment is further segmented into imaging, biopsies, and blood tests. The imaging segment includes computerized tomography (CT), magnetic resonance imaging (MRI), X-Ray, positron emission tomography (PET) and others. The biopsies segment includes needle biopsy and surgical biopsy. The blood tests segment includes alkaline phosphatase profiling, lactate dehydrogenase profiling, and others.
On the basis of end-user, the osteosarcoma market has been segmented into hospitals & clinics, diagnostic centers, and academic & research organizations. Its hold largest market share can be attributed to an increase in the number of patients who have cancer, coupled with a rise in a number of hospitals, and quality care, and availability of skilled and qualified professionals.
The Osteosarcoma Market is broadly segmented based on region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas accounted for a market share of 40.02% in 2018. Americas is sub-segmented into North America and South America. North America has been further sub-segmented into the US and Canada.
Europe was the second-largest osteosarcoma market in 2018. The Europe region is further segmented into Western Europe and Eastern Europe. Western Europe, on the basis of countries, has been segmented into Germany, the UK, France, Italy, Spain, and the rest of Western Europe.
The Asia-Pacific region has been categorized as China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. It holds the third-largest position in the osteosarcoma market.
The market in the Middle East & Africa is likely to exhibit the lowest growth due to factors such as limited access to and availability of treatment facilities. However, the high prevalence of bone cancer population would support the growth of the market in the region during the forecast period.
Prominent Players
The Prominent Players in the Market Pfizer Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Baxter, Novartis AG, Aurobindo Pharma, Hikma Pharmaceuticals PLC, Mylan N.V., and ADVAXIS, INC. The players operating in the osteosarcoma market are focusing on product launches, along with expanding their global footprints by entering untapped markets.
Intended Audience
| Report Attribute/Metric | Details |
| Market Size | USD 1.21 Billion |
| Compound Annual Growth Rate (CAGR) | 6.39% (2024-2032) |
| Base Year | 2021 |
| Market Forecast Period | 2024-2034 |
| Historical Data | 2018 & 2020 |
| Market Forecast Units | Value (USD million) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Molecule, Indication |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Pfizer Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Baxter, Novartis AG, Aurobindo Pharma, Hikma Pharmaceuticals PLC, Mylan N.V., and ADVAXIS, INC. |
| Key Market Opportunities | The major companies are rigorously investing in R&D |
| Key Market Dynamics | Growing research and development efforts and increasing awareness about early diagnosis are driving the osteosarcoma market, while challenges in treatment innovation and limited therapeutic options pose significant constraints. |
Osteosarcoma Market Highlights:
Frequently Asked Questions (FAQ) :
Osteosarcoma Market is projected to grow at a 6.39% CAGR between 2024-2032.
The Americas is expected to dominate the Osteosarcoma Market.
Osteosarcoma Market is predicted to touch USD 1.21 Billion by 2032.
Different end users of the Osteosarcoma Market include diagnostic centers, hospitals and clinics, and academic and research organizations.
Side effects of chemotherapy and high treatment cost may limit the Osteosarcoma Market growth.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
